期刊
CANCERS
卷 13, 期 20, 页码 -出版社
MDPI
DOI: 10.3390/cancers13205162
关键词
esophageal cancer; neoadjuvant therapy; chemotherapy; chemoradiotherapy; immunotherapy; esophagectomy; active surveillance
类别
资金
- National Natural Science Foundation of China [31800675]
- Postdoctoral Science Foundation in Jiangsu Province [2018K263C]
- Key Project for Social Development in Jiangsu Province [BE-2019698]
- Strengthening Health Care via Science and Education Project and Clinical Medical Innovation Platform Foundation of Yangzhou [YXZX20184]
- Major Public Health Projects in Yangzhou: Screening projects of early gastrointestinal diseases (2018)
Neoadjuvant therapy, including chemotherapy and chemoradiotherapy, has been shown to improve overall survival in patients with locally advanced resectable esophageal cancer. However, controversies persist regarding the optimal combination of neoadjuvant treatments and the need for further investigations to optimize protocols and surveillance strategies.
Simple Summary Neoadjuvant therapy is recommended as standard care for patients with locally advanced resectable esophageal cancer. Neoadjuvant chemotherapy (nCT) and chemoradiotherapy (nCRT) have convincingly been shown to improve the survival rate compared with surgery alone based on the results of several randomized clinical trials. Immunotherapy has become a new research direction in the field of EC research due to its great curative effects. However, controversies still remain in regard to identifying the most appropriate combination of nCT, nCRT, immunotherapy, and surgery, optimizing more effective neoadjuvant treatment protocols and surveillance strategies. This review comprehensively summarizes the research progress and describes and discusses the outcomes, pros, and cons of current trials. We believe our work has great academic value and will be of great help for researchers to understand the domestic and foreign research status in the field of neoadjuvant therapy in EC. Neoadjuvant therapies, primarily chemotherapy and chemoradiotherapy, are able to improve the overall survival (OS) in patients with locally advanced resectable esophageal cancer (EC) based on the results of several randomized clinical trials. The advantage of neoadjuvant therapy is chiefly attributed to the decreased risk of local-regional recurrence and distant metastasis. Thus, it has been recommended as standard treatment for patients with resectable EC. However, several fundamental problems remain. First, the combination of neoadjuvant chemotherapy (nCT), neoadjuvant chemoradiotherapy (nCRT), and surgery for EC patients with different histological types remain controversial. Furthermore, to reduce the toxicity of preoperative chemotherapy and the risk of complications caused by preoperative radiation therapy, the treatment protocols of nCT and nCRT still need to be investigated and optimized by prospective trials. Moreover, for patients with complete clinical response following neoadjuvant therapy, it is worth ascertaining whether a watch and wait surveillance plus surgery-as-needed policy is more favorable, as well as, in addition to preoperative chemoradiotherapy, whether immunotherapy, especially when combined with the traditional neoadjuvant therapy regimens, brings new prospects for EC treatment. In this review, we summarize the recent insights into the research progress and existing problems of neoadjuvant therapy for locally advanced resectable EC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据